A Phase 3, Long-Term, Open-Label Safety Study of Self-Administered Galcanezumab Injections in Patients with Migraine

被引：0
|
作者：
Stauffer, Virginia L. [1 ]
Sides, Ryan [1 ]
Camporeale, Angelo [1 ]
Skljarevski, Vladimir [1 ]
Ahl, Jonna [1 ]
Aurora, Sheena K. [1 ]
机构：
[1] Eli Lilly & Co, Indianapolis, IN 46285 USA
来源：
CEPHALALGIA | 2017年 / 37卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
PO-01-184
引用
收藏
页码：330 / 331
页数：2
相关论文
共 50 条
  • [11] Long-term treatment with galcanezumab in patients with chronic migraine: results from the open-label extension of the REGAIN study
    Pozo-Rosich, Patricia
    Detke, Holland C.
    Wang, Shufang
    Dolezil, David
    Li, Lily Q.
    Aurora, Sheena K.
    Reuter, Uwe
    CURRENT MEDICAL RESEARCH AND OPINION, 2022, 38 (05) : 731 - 742
  • [12] Open-label, long-term safety study of zonisamide administered to children with epilepsy
    Shinnar, S
    Pellock, JM
    Conry, JA
    NEUROLOGY, 2006, 66 (05) : A37 - A37
  • [13] Long-term safety of zavegepant nasal spray for the acute treatment of migraine: A phase 2/3 open-label study
    Mullin, Kathleen
    Croop, Robert
    Mosher, Linda
    Fullerton, Terence
    Madonia, Jennifer
    Lipton, Richard B.
    CEPHALALGIA, 2024, 44 (08)
  • [14] Galcanezumab in patients with episodic migraine: results from the open-label period of the phase 3 PERSIST study
    Zhou, Jiying
    Zhong, Lianmei
    Chowdhury, Debashish
    Skorobogatykh, Kirill
    Luo, Guogang
    Yang, Xiaosu
    Zhang, Mingjie
    Sun, Lingli
    Liu, Hui
    Qian, Chenxi
    Yu, Shengyuan
    JOURNAL OF HEADACHE AND PAIN, 2023, 24 (01):
  • [15] Galcanezumab in patients with episodic migraine: results from the open-label period of the phase 3 PERSIST study
    Jiying Zhou
    Lianmei Zhong
    Debashish Chowdhury
    Kirill Skorobogatykh
    Guogang Luo
    Xiaosu Yang
    Mingjie Zhang
    Lingli Sun
    Hui Liu
    Chenxi Qian
    Shengyuan Yu
    The Journal of Headache and Pain, 24
  • [16] Open-label, long-term safety study of zonisamide administered to children and adolescents with epilepsy
    Shinnar, Shlomo
    Pellock, John M.
    Conry, Joan A.
    EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY, 2009, 13 (01) : 3 - 9
  • [17] Assessment of prolonged safety and tolerability of erenumab in migraine patients in a long-term open-label study (APOLLON)
    Goebel, Hartmut
    Schlegel, Eugen
    Jaeger, Kathrin
    Ortler, Sonja
    Leist, Lea
    JOURNAL OF HEADACHE AND PAIN, 2024, 25 (01):
  • [18] A multicenter, open-label long-term safety study of rimegepant for the acute treatment of migraine
    Croop, Robert
    Berman, Gary
    Kudrow, David
    Mullin, Kathleen
    Thiry, Alexandra
    Lovegren, Meghan
    L'Italien, Gilbert
    Lipton, Richard B.
    CEPHALALGIA, 2024, 44 (04)
  • [19] Long-term safety and tolerability of eptinezumab in patients with chronic migraine: a 2-year, open-label, phase 3 trial
    Kudrow, David
    Cady, Roger K.
    Allan, Brent
    Pederson, Susan M.
    Hirman, Joe
    Mehta, Lahar R.
    Schaeffler, Barbara A.
    BMC NEUROLOGY, 2021, 21 (01)
  • [20] Long-term safety and tolerability of eptinezumab in patients with chronic migraine: a 2-year, open-label, phase 3 trial
    David Kudrow
    Roger K. Cady
    Brent Allan
    Susan M. Pederson
    Joe Hirman
    Lahar R. Mehta
    Barbara A. Schaeffler
    BMC Neurology, 21
12345